International guidelines for management of metastatic breast cancer: Can metastatic breast cancer be cured?

Journal of the National Cancer Institute

Volumn 102, Issue 7, 2010, Pages 456-463

  Pagani, Olivia ^a,b   Senkus, Elbieta ^c   Wood, William ^d   Colleoni, Marco ^e   Cufer, Tanja ^f   Kyriakides, Stella ^g   Costa, Alberto ^h,i   Winer, Eric P ^j   Cardoso, Fatima ^k  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^g European Breast Cancer Coalition   (Cyprus)

^h EUROPEAN SCHOOL OF ONCOLOGY   (Italy)

ⁱ IRCCS   (Italy)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k JULES BORDET INSTITUTE   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; LAPATINIB; NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANIMAL; BONE TUMOR; BREAST TUMOR; CANCER STAGING; CATHETER ABLATION; CONSENSUS DEVELOPMENT; DOSE RESPONSE; EARLY DIAGNOSIS; EUROPE; FEMALE; GENE EXPRESSION PROFILING; IMMUNOLOGY; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; LIVER TUMOR; LUNG TUMOR; METABOLISM; OBSERVER VARIATION; ORGANIZATION; PATHOLOGY; PATIENT CARE; PATIENT SELECTION; REVIEW; SURVIVAL RATE; TUMOR EMBOLISM;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; EARLY DETECTION OF CANCER; EUROPE; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; LIVER NEOPLASMS; LUNG NEOPLASMS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; OBSERVER VARIATION; PATIENT CARE TEAM; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE;

EID: 77950556303     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq029     Document Type: Note

References (101)

1. Andre F, Slimane K, Bachelot T, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004;22(16):3302-3308. (Pubitemid 41103686)
2. Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer. 2004;100(1):44-52.
3. Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110(5):973-979. (Pubitemid 47312861)
4. Mahner S, Schirrmacher S, Brenner W, et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol. 2008;19(7):1249-1254. (Pubitemid 351911953)
5. Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol. 2008;26(5):712-720. (Pubitemid 351264383)
6. Hanrahan EO, Broglio KR, Buzdar AU, et al. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer. 2005;104(6):1158-1171.
7. Network NCC. 2008 NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 2. 2008.
8. Kataja V, Castiglione M. on behalf of the ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(suppl 2):ii11-ii13.
9. Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. Breast. 2007;16(1):9-10.
10. Tait CR, Waterworth A, Loncaster J, et al. The oligometastatic state in breast cancer: hypothesis or reality. Breast. 2005;14(2):87-93. (Pubitemid 40353035)
11. Andreopoulou E, Hortobagyi GN. Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. J Clin Oncol. 2008;26(22):3660-3662.
12. Dawood S, Broglio K, Valero V, et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer. 2008;113(9):2422-2430.
13. Singletary SE, Walsh G, Vauthey JN, et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist. 2003;8(3):241-251. (Pubitemid 36648810)
14. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26(12):1987-1992.
15. Miksad RA, Zietemann V, Gothe R, et al. Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care. 2008;24(4):371-383.
16. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(suppl 3):20-29. (Pubitemid 43152727)
17. Tomiak E, Piccart M, Mignolet F, et al. Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study. Eur J Cancer. 1996;32A(11):1876-1887. (Pubitemid 26361679)
18. Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14(8):2197-2205. (Pubitemid 26264869)
19. Rahman ZU, Frye DK, Smith TL, et al. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. Cancer. 1999;85(1):104-111.
20. Decker DA, Ahmann DL, Bisel HF, et al. Complete responders to chemotherapy in metastatic breast cancer. Characterization and analysis. JAMA. 1979;242(19):2075-2079. (Pubitemid 10204051)
21. Pierga JY, Asselain B, Jouve M, et al. Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy. Cancer. 2001;91(6):1079-1089. (Pubitemid 32295413)
22. Bruzzi P, Del Mastro L, Sormani MP, et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol. 2005;23(22):5117-5125. (Pubitemid 46224020)
23. Hackshaw A, Knight A, Barrett-Lee P, Leonard R. Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. Br J Cancer. 2005;93(11):1215-1221. (Pubitemid 41679406)
24. Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26(12):1980-1986.
25. Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer. 2005;93(3):293-301. (Pubitemid 43080031)
26. Cardoso F, Di Leo A, Lohrisch C, Bernard C, Ferreira F, Piccart MJ. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol. 2002;13(2):197-207. (Pubitemid 34704970)
27. Jackisch C. HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncologist. 2006;11(suppl 1):34-41.
28. Farquhar C, Marjoribanks J, Basser R, et al. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev. 2005;(3):CD003142.
29. Kröger N, Frick M, Gluz O, et al. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. J Clin Oncol. 2006;24(24):3919-3926. (Pubitemid 46630740)
30. Crump M, Gluck S, Tu D, et al. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol. 2008;26(1):37-43.
31. Schmid P, Schippinger W, Nitsch T, et al. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol. 2005;23(3):432-440. (Pubitemid 46224218)
32. Vredenburgh JJ, Madan B, Coniglio D, et al. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant. 2006;37(11):1009-1015. (Pubitemid 43753463)
33. Biron P, Durand M, Roché H, et al. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant. 2008;41(6):555-562. (Pubitemid 351472147)
34. Kurian S, Qazilbash M, Fay J, et al. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit. Breast J. 2006;12(6):531-535. (Pubitemid 44690841)
35. Vredenburgh JJ, Coniglio D, Broadwater G. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol Blood Marrow Transplant. 2006;12(2):195-203. (Pubitemid 43138014)
36. Buzdar AU, Blumenschein GR, Smith TL, et al. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). J Surg Oncol. 1979;12(1):27-40.
37. Buzdar AU, Blumenschein GR, Montague ED, et al. Combined modality approach in breast cancer with isolated or multiple metastases. Am J Clin Oncol. 1984;7(1):45-50. (Pubitemid 14158430)
38. Holmes FA, Buzdar AU, Kau SW, et al. Combined-modality approach for patients with isolated recurrences of breast cancer (IV-NED): the M.D. Anderson experience. Breast Dis. 1994;7:7-20.
39. Rivera E, Holmes FA, Buzdar AU, et al. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J. 2002;8(1):2-9. (Pubitemid 34118477)
40. Nieto Y, Cagnoni PJ, Shpall EJ, et al. Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease. Clin Cancer Res. 1999;5(7):1731-1737. (Pubitemid 29334453)
41. Nieto Y, Nawaz S, Jones RB, et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol. 2002;20(3):707-718. (Pubitemid 34111378)
42. Fraschini G, Fleishman G, Yap HY, et al. Percutaneous hepatic arterial infusion of cisplatin for metastatic breast cancer. Cancer Treat Rep. 1987;71(3):313-315. (Pubitemid 17051736)
43. Fraschini G, Fleishman G, Charnsangavej C, Carrasco CH, Hortobagyi GN. Continuous 5-day infusion of vinblastine for percutaneous hepatic arterial chemotherapy for metastatic breast cancer. Cancer Treat Rep. 1987;71(11):1001-1005. (Pubitemid 18002206)
44. Fraschini G, Charnsangavej C, Carrasco CH, Buzdar AU, Jabboury KW, Hortobagyi GN. Percutaneous hepatic arterial infusion of cisplatin-vinblastine for refractory breast carcinoma metastatic to the liver. Am J Clin Oncol. 1988;11(1):34-38. (Pubitemid 18061718)
45. Malayeri R, Wein W, Zielinski C. Effective intrahepatic administration of gemcitabine after failure of doxorubicin in metastatic breast cancer. Eur J Cancer. 1997;33(14):2435. (Pubitemid 28129190)
46. Camacho LH, Kurzrock R, Cheung A. Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver. Cancer. 2007;109(11):2190-2196. (Pubitemid 46801547)
47. Ries L, Eisner M, Kosary C, et al. SEER Cancer Statistics Review, 1975-2000. Bethesda, MD: National Cancer Institute; 2003. http://seer.cancer. gov/csr/1975-2000.
48. Wood WC. Breast surgery in advanced breast cancer: local control in the presence of metastases. Breast. 2007;16(suppl 2):S63-S66.
49. Khan SA. Does resection of an intact breast primary improve survival in metastatic breast cancer? Oncology. 2007;21(8):924-931. (Pubitemid 47106305)
50. Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery. 2002;132(4):620-626. (Pubitemid 35247324)
51. Babiera GV, Rao R, Feng L, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol. 2006;13(6):776-782. (Pubitemid 43727360)
52. Fields RC, Jeffe DB, Trinkaus K, et al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol. 2007;14(12):3345-3351. (Pubitemid 350160108)
53. Morrow M, Goldstein L. Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted? J Clin Oncol. 2006;24(18):2694-2696. (Pubitemid 46630562)
54. Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother. 2005;54(11):1137-1142. (Pubitemid 41396817)
55. Gnerlich J, Jeffe DB, Deshpande AD, et al. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data. Ann Surg Oncol. 2007;14(8):2187-2194. (Pubitemid 47174926)
56. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655-1659.
57. Hotta T, Takifuji K, Arii K, et al. Potential predictors of long-term survival after surgery for patients with stage IV colorectal cancer. Anticancer Res. 2006;26(2B):1377-1383.
58. Young SE, Martinez SR, Essner R. The role of surgery in treatment of stage IV melanoma. J Surg Oncol. 2006;94(4):344-351. (Pubitemid 44330859)
59. Retsky M, Bonadonna G, Demicheli R, et al. Hypothesis: induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res. 2004;6(4):R372-R374.
60. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79(2):315-328. (Pubitemid 24324921)
61. Salo M. Effects of anaesthesia and surgery on the immune response. Acta Anaesthesiol Scand. 1992;36(3):201-220.
62. Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;24(18):2743-2749. (Pubitemid 46630571)
63. Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg. 2008;247(5):732-738. (Pubitemid 351591506)
64. Rao R, Feng L, Kuerer HM, et al. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol. 2008;15(6):1696-1702.
65. Khan SA, Stewart AK, Morrow M. Does local therapy of the intact primary tumor in stage 4 breast cancer affect survival? Proc ASCO. 2003;22:81.
66. Carmichael AR, Anderson ED, Chetty U, Dixon JM. Does local surgery have a role in the management of stage IV breast cancer? Eur J Surg Oncol. 2003;29(1):17-19. (Pubitemid 36181771)
67. Olson JA Jr, Marcom PK. Benefit or bias? The role of surgery to remove the primary tumor in patients with metastatic breast cancer. Ann Surg. 2008;247(5):739-740.
68. Alvarado M, Ewing CA, Elyassnia D, Foster RD, Shelley HE. Surgery for palliation and treatment of advanced breast cancer. Surg Oncol. 2007;16(4):249-257. (Pubitemid 350192234)
69. Planchard D, Soria JC, Michiels S, et al. Uncertain benefit from surgery in patients with lung metastases from breast carcinoma. Cancer. 2004;100(1):28-35. (Pubitemid 37553536)
70. Friedel G, Pastorino U, Ginsberg RJ, et al. Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur J Cardiothorac Surg. 2002;22(3):335-344. (Pubitemid 36153060)
71. Friedel G, Linder A, Toomes H. The significance of prognostic factors for the resection of pulmonary metastases of breast cancer. Thorac Cardiovasc Surg. 1994;42(2):71-75. (Pubitemid 24150561)
72. Murabito M, Salat A, Mueller MR. Complete resection of isolated lung metastasis from breast carcinoma results in a strong increase in survival. Minerva Chir. 2000;55(3):121-127. (Pubitemid 30237531)
73. McDonald ML, Deschamps C, Ilstrup DM, et al. Pulmonary resection for metastatic breast cancer. Ann Thorac Surg. 1994;58(6):1599-1602. (Pubitemid 24378963)
74. Livartowski A, Chapelier A, Beuzeboc P, et al. Surgical excision of pulmonary metastasis of cancer of the breast: apropos of 40 patients. Bull Cancer. 1998;85(9):799-802.
75. Tanaka F, Li M, Hanaoka N, et al. Surgery for pulmonary nodules in breast cancer patients. Ann Thorac Surg. 2005;79(5):1711-1714. (Pubitemid 40614593)
76. Lanza LA, Natarajan G, Roth JA, Putnam JB Jr. Long-term survival after resection of pulmonary metastases from carcinoma of the breast. Ann Thorac Surg. 1992;54(2):244-247.
77. Staren ED, Salerno C, Rongione A, et al. Pulmonary resection for metastatic breast cancer. Arch Surg. 1992;127(11):1282-1284.
78. Girard P, Baldeyrou P, Le CT, Le CA, Brigandi A, Grunenwald D. Surgery for pulmonary metastases. Who are the 10-year survivors? Cancer. 1994;74(10):2791-2797. (Pubitemid 24340545)
79. McCormack PM, Bains MS, Beattie EJ Jr, Martini N. Pulmonary resection in metastatic carcinoma. Chest. 1978;73(2):163-166. (Pubitemid 8292799)
80. Rena O, Papalia E, Ruffini E, et al. The role of surgery in the management of solitary pulmonary nodule in breast cancer patients. Eur J Surg Oncol. 2007;33(5):546-550. (Pubitemid 46746529)
81. Ludwig C, Stoelben E, Hasse J. Disease-free survival after resection of lung metastases in patients with breast cancer. Eur J Surg Oncol. 2003;29(6):532-535. (Pubitemid 37009971)
82. Mountain CF, Khalil KG, Hermes KE, Frazier OH. The contribution of surgery to the management of carcinomatous pulmonary metastases. Cancer. 1978;41(3):833-840. (Pubitemid 8313217)
83. Adam R, Aloia T, Krissat J, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg. 2006;244(6):897-907. (Pubitemid 44808622)
84. Pocard M, Pouillart P, Asselain B, et al. Hepatic resection for breast cancer metastases: results and prognosis (65 cases). Ann Chir. 2001;126(5):413-420. (Pubitemid 32374999)
85. Elias D, Maisonnette F, Druet-Cabanac M, et al. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg. 2003;185(2):158-164. (Pubitemid 36143907)
86. Pocard M, Pouillart P, Asselain B, Salmon R. Hepatic resection in metastatic breast cancer: results and prognostic factors. Eur J Surg Oncol. 2000;26(2):155-159. (Pubitemid 30242938)
87. Raab R, Nussbaum KT, Behrend M, Weimann A. Liver metastases of breast cancer: results of liver resection. Anticancer Res. 1998;18(3C):2231-2233. (Pubitemid 28386496)
88. Sakamoto Y, Yamamoto J, Yoshimoto M, et al. Hepatic resection for metastatic breast cancer: prognostic analysis of 34 patients. World J Surg. 2005;29(4):524-527. (Pubitemid 41125381)
89. Vlastos G, Smith DL, Singletary SE, et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol. 2004;11(9):869-874. (Pubitemid 40568815)
90. Yoshimoto M, Tada T, Saito M, et al. Surgical treatment of hepatic metastases from breast cancer. Breast Cancer Res Treat. 2000;59(2):177-184. (Pubitemid 30216141)
91. Elias D, Lasser PH, Montrucolli D, et al. Hepatectomy for liver metastases from breast cancer. Eur J Surg Oncol. 1995;21(5):510-513.
92. Ercolani G, Grazi GL, Ravaioli M, et al. The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases. Ann Surg Oncol. 2005;12(6):459-466. (Pubitemid 40884260)
93. Pocard M, Salmon RJ. Hepatic resection for breast cancer metastasis. The concept of adjuvant surgery. Bull Cancer. 1997;84(1):47-50. (Pubitemid 27099616)
94. Ramming KP. Surgery for pulmonary metastases. Surg Clin North Am. 1980;60(4):815-824.
95. Casey JJ, Stempel BG, Scanlon EF, Fry WA. The solitary pulmonary nodule in the patient with breast cancer. Surgery. 1984;96(4):801-805. (Pubitemid 14019729)
96. Bathe OF, Kaklamanos IG, Moffat FL, et al. Metastasectomy as a cytoreductive strategy for treatment of isolated pulmonary and hepatic metastases from breast cancer. Surg Oncol. 1999;8(1):35-42.
97. Blazer DG III, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26(33):5344-5351.
98. Selzner M, Morse MA, Vredenburgh JJ, et al. Liver metastases from breast cancer: long-term survival after curative resection. Surgery. 2000;127(4):383-389. (Pubitemid 30225989)
99. Jakobs TF, Hoffmann RT, Schrader A, et al. CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. Cardiovasc Intervent Radiol. 2009;32(1):38-46.
100. Gunabushanam G, Sharma S, Thulkar S, et al. Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients. J Vasc Interv Radiol. 2007;18(1 pt 1):67-72. (Pubitemid 46616669)
101. Sofocleous CT, Nascimento RG, Gonen M, et al. Radiofrequency ablation in the management of liver metastases from breast cancer. AJR Am J Roentgenol. 2007;189(4):883-889. (Pubitemid 47479772)